Zimhi - A Higher-Dose Injectable Naloxone for Opioid Overdose
Date: April 18, 2022
Issue #:
1648Summary:
The FDA has approved a higher-dose injectable
formulation of the opioid antagonist naloxone
(Zimhi– Adamis) for emergency treatment of opioid
overdose. A single IM or SC injection of the new
formulation delivers 5 mg of naloxone; injectable
formulations that deliver 0.4 mg or 2 mg of the drug
have been available for years. Naloxone is also
available in intranasal formulations for the same
indi cation (see Table 1).
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Drug abuse Kloxxado Naloxone Narcan opioid abuse Opioid dependence Opioids Zimhi Source Type: research